Billionaire Profile
Satish Mehta
Global Rank
#2196

Image: Ministry of Culture | GODL-India | via Wikimedia Commons

Satish Mehta

CEO, Pharmaceuticals
INDIA
Real-Time Net Worth
$1.896B
Estimated based on Pharmaceuticals stock value as of June 5, 2026
+1.83% (24h)
Age
75
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
INDIA

Biography

Satish Mehta is a prominent figure in the pharmaceutical industry and a successful entrepreneur. He is the founder of Emcure Pharmaceuticals, one of India's leading pharmaceutical companies, and has built a diverse portfolio of investments. His career spans over four decades, during which he has overseen Emcure's growth into a global enterprise with operations in over 70 countries. Mehta's net worth reflects his successful ventures in pharmaceuticals and his ability to build and expand the company. He is recognized for his commitment to making healthcare accessible and affordable.

Fact Checked
Verified by Editorial Team
Live Data
Updated 6/5/2026
Report a Correction

Wealth Over Time

Career Milestones

  1. 1

    Founded Emcure Pharmaceuticals

    Started Emcure as a contract manufacturer for multinationals.

  2. 2

    Sun Pharma listed on the stock exchange

    Sun Pharma was listed on the stock exchange with an oversubscribed issue.

  3. 3

    Entered regulated markets

    Emcure started building operations in various countries.

  4. 4

    Emcure Pharmaceuticals listed on the stock exchange

    Emcure was listed at a 31% premium.

Net Worth History

YearNet Worth
2026$1.896B
2025$1.7B
2024$1.7B

Philanthropy

Sponsorship of life-saving surgeries

$Undisclosed
Healthcare

Emcure supports medical initiatives.

Education for underprivileged students

$Undisclosed
Education

Supports educational programs.

Village adoption and environmental sustainability

$Undisclosed
Environmental

Promoting awareness about environmental sustainability.

PRERNA initiative

$Undisclosed
Social Empowerment

Empowers women employees

NEEM scheme

$Undisclosed
Skill Development

Boosts skill development.

Controversies & Legal

2017

Price Fixing Scandal

Related to Heritage Pharmaceuticals, a US subsidiary of Emcure.

In-Depth Profile

Early Life and Education

Satish Mehta's journey began with a vision to revolutionize healthcare in India. After graduating from IIM Ahmedabad, he decided to embark on an entrepreneurial path, setting the stage for Emcure Pharmaceuticals. His father was a pharma retailer, which gave him early insights into the industry.

Rise to Success

Founded in 1981 with a loan of ₹3 lakh, Emcure Pharmaceuticals rapidly grew under Satish Mehta's leadership. The company initially focused on contract manufacturing and gradually expanded into branded generics. Under his leadership, Emcure became a leading pharmaceutical company in India and then expanded globally.

Key Business Strategies

Mehta's leadership emphasized innovation and strategic acquisitions. Emcure invested significantly in research and development and expanded its product portfolio through both organic growth and strategic acquisitions. This approach helped the company enter global markets, particularly the US. Furthermore, Emcure went public in July 2024, listed at a premium, to further its expansion.

Philanthropy

Satish Mehta believes in giving back to society. Emcure sponsors life-saving surgeries, supports education for underprivileged students, and has adopted villages to promote environmental sustainability. His PRERNA initiative empowers women employees, and the NEEM scheme boosts skill development, reinforcing Emcure's commitment to community. Also, Mehta has been recognized with the 'India for Humanity' initiative.

Career Milestones

1981

Founded Emcure Pharmaceuticals

Started Emcure as a contract manufacturer for multinationals.

1994

Sun Pharma listed on the stock exchange

Sun Pharma was listed on the stock exchange with an oversubscribed issue.

2005-2006

Entered regulated markets

Emcure started building operations in various countries.

2024

Emcure Pharmaceuticals listed on the stock exchange

Emcure was listed at a 31% premium.

Philanthropy & Social Impact

Healthcare

Sponsorship of life-saving surgeries

Undisclosed

Emcure supports medical initiatives.

Education

Education for underprivileged students

Undisclosed

Supports educational programs.

Environmental

Village adoption and environmental sustainability

Undisclosed

Promoting awareness about environmental sustainability.

Social Empowerment

PRERNA initiative

Undisclosed

Empowers women employees

Skill Development

NEEM scheme

Undisclosed

Boosts skill development.

Business Philosophy & Leadership

Notable Quotes

"Money is a part of it. But the need to achieve higher goals is what propels me."

Leadership Principles

Focus on Innovation

Investing in R&D to develop cutting-edge molecules and differentiated products.

Socially Committed Enterprise

Emphasizing philanthropy and community development.

Strategic Global Expansion

Prioritizing a strong base in India before expanding into international markets.

Controversies & Challenges

2017

Price Fixing Scandal

Related to Heritage Pharmaceuticals, a US subsidiary of Emcure.